PD-L1 immunohistochemical expression varies among different TETs, ranging from 13% of type A to 76% of type B3 thymomas, and to 53% of thymic carcinomas [6], and it has been linked to shorter survival [133]. Here, CD274 is linked to thymic carcinoma.